Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
Cancers · 13.06.2023 · 15 (12) · 3172
DOI: 10.3390/cancers15123172 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.06.2023. Verfasst von Enrico Sammarco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, 56126 Pisa, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line therapy after first-line treatment with immune checkpoint inhibitors are limited to small phase II studies. As with other solid tumors (such as melanoma and non-small cell lung cancer), preliminary data about the clinical efficacy of rechallenge of immunotherapy (alone or in combination with other drugs) in renal cell carcinoma are beginning to emerge. Nevertheless, the role of rechallenge in immunotherapy in this setting of disease remains unclear and cannot be considered a standard of care; currently some randomized trials are exploring this approach in patients with metastatic renal cell carcinoma. The aim of our review is to summarize main evidence available in the literature concerning immunotherapy rechallenge in renal carcinoma, especially focusing on biological rationale of resistance to immune checkpoint inhibitors, on the published data of clinical efficacy and on future perspectives.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, 56126 Pisa, Italy.
- Unit of Medical Oncology 1, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, 56126 Pisa, Italy.
ORCID-Profile: Enrico Sammarco, Amedeo Nuzzo
Zitieren
APA
Sammarco, E., Manfredi, F., Nuzzo, A., Ferrari, M., Bonato, A., Salfi, A., Serafin, D., Zatteri, L., Antonuzzo, A., & Galli, L. (2023). Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions. Cancers, 15(12), 3172. https://doi.org/10.3390/cancers15123172
Vancouver
Sammarco E, Manfredi F, Nuzzo A, Ferrari M, Bonato A, Salfi A, et al. Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions. Cancers. 2023;15(12):3172. doi:10.3390/cancers15123172
BibTeX
@article{Sammarco2023,
author = {Sammarco, Enrico and Manfredi, Fiorella and Nuzzo, Amedeo and Ferrari, Marco and Bonato, Adele and Salfi, Alessia and Serafin, Debora and Zatteri, Luca and Antonuzzo, Andrea and Galli, Luca},
title = {Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions},
journal = {Cancers},
year = {2023},
volume = {15},
number = {12},
pages = {3172},
doi = {10.3390/cancers15123172}
}
EUVIMED